FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2963067539> ?p ?o ?g. }

• W2963067539 endingPage "1700" @default.
• W2963067539 startingPage "1700" @default.
• W2963067539 abstract "Abstract Myelodysplastic Syndromes (MDS) are a heterogeneous group of diseases, characterized by the clonal acquisition of somatic point mutations and chromosomal alterations. Conventional karyotyping remains one of the most important tools for MDS diagnosis because several cytogenetics abnormalities can be used to stratify patients into subtypes with different prognoses. However, a non-informative cytogenetics due to normal or unsuccessful karyotype could lead to an erroneous estimation of the prognostic risk. To overcome this drawback, we assessed the reliability of a single Next-Generation Sequencing (NGS) assay to simultaneously detect Single Nucleotide Variations (SNVs), including small indels, as well as Copy Number Alterations (CNAs) and copy-neutral Loss of Heterozygosity (cnLOH) for diagnostic application. We combined a custom panel, targeting 40 genes frequently implicated in myeloid neoplasms, with a target enrichment design (OneSeq, Agilent®), having a genome-wide backbone resolution of 1 Mb and 10 Mb for CNAs and cnLOH, respectively. Sequencing libraries were prepared following the “SureSelectQXT Library Prep” protocol and sequenced using the NextSeq 500 platform (Illumina®). Data processing and variant annotation were performed using an integrated in-house bioinformatic pipeline. SNVs and small indels were selected based on allele frequency (VAF ≥ 3%), their absence in the healthy population (UCSC Common SNP; MAF We performed a pilot study with a cohort of 30 patients clinically diagnosed with primary MDS at La Fe University Hospital in Valencia. Samples were analysed in parallel by NGS and CytoScanTM HD array (Affymetrix®) in order to establish criteria and thresholds for accurate filtering of sequencing data, especially for CNA identification and calculation of analytical sensitivity. Currently, we are evaluating the reliability of these criteria in a separate cohort of 30 additional patients. Preliminary results in the test cohort showed that we were able to identify at least one point mutation in 29 of 30 patients, with an average of 2 mutations per sample (range 0-7). Mutations were detected in 20 of the 40 genes covered in the panel. The epigenetic modifier TET2 was the most frequently mutated gene in the cohort (9 of 30 cases), followed by two splicing genes, SF3B1 and SRSF2 (each 8 of 30). In addition, we observed some of the described gene correlations, such as the co-occurrence of mutations in IDH2 and SRSF2 genes and the mutually exclusive presence of SF3B1 and SRSF2 . Although cytogenetic studies identified chromosomal abnormalities in 9 of 30 of cases, the number of MDS-related copy number changes detected by sequencing increased to 20 cases, including 9 with normal and 1 with unsuccessful karyotype. We observed the frequent CNAs, such as chromosome 5q and 7q deletions, 4 and 3 cases, respectively, the complete duplication of chr21 in 1 case and 9 cnLOH events. Interestingly, in patients with normal karyotype, although we focused on large chromosomal abnormalities, we have detected at least 3 small events (6-14 Mb) leading to focal deletions of ETV6, BTG1 and RUNX1 genes, as well as 6 cnLOH events, 2 of which involved chr7q22q36. We obtained a high level of concordance between clinical relevant CNAs larger than 1 Mb identified by the CytoScanTM HD array and our sequencing approach. However, the variation in probe distribution in the two backbones was responsible for differences in the detected sizes of deletions and duplications in ~10% of the observed CNAs. This NGS strategy allowed the identification of point mutations and large chromosomal alterations with a resolution of 1 Mb using a single assay, as well as other alterations invisible to conventional cytogenetics, such as cnLOH. Although automating the bioinformatic pipeline is still ongoing, this study demonstrated that a comprehensive NGS-based genomic approach could contribute to improve MDS diagnosis and prognosis. Disclosures Sanz: Gamida Cell: Research Funding." @default.
• W2963067539 created "2019-07-30" @default.
• W2963067539 creator A5003232266 @default.
• W2963067539 creator A5016773523 @default.
• W2963067539 creator A5017341923 @default.
• W2963067539 creator A5020519105 @default.
• W2963067539 creator A5023063042 @default.
• W2963067539 creator A5034624734 @default.
• W2963067539 creator A5037330717 @default.
• W2963067539 creator A5039824498 @default.
• W2963067539 creator A5043157565 @default.
• W2963067539 creator A5052934298 @default.
• W2963067539 creator A5053353486 @default.
• W2963067539 creator A5057486427 @default.
• W2963067539 creator A5059839538 @default.
• W2963067539 creator A5066552050 @default.
• W2963067539 creator A5082287365 @default.
• W2963067539 creator A5083527191 @default.
• W2963067539 creator A5085518228 @default.
• W2963067539 creator A5087077844 @default.
• W2963067539 creator A5089354375 @default.
• W2963067539 creator A5091055565 @default.
• W2963067539 creator A5091201610 @default.
• W2963067539 date "2017-12-07" @default.
• W2963067539 modified "2023-09-27" @default.
• W2963067539 title "A Novel Single Next-Generation Sequencing (NGS) Approach for the Molecular Karyotyping and Genotyping of Patients with Myelodysplastic Syndromes" @default.
• W2963067539 doi "https://doi.org/10.1182/blood.v130.suppl_1.1700.1700" @default.
• W2963067539 hasPublicationYear "2017" @default.
• W2963067539 type Work @default.
• W2963067539 sameAs 2963067539 @default.
• W2963067539 citedByCount "0" @default.
• W2963067539 crossrefType "journal-article" @default.
• W2963067539 hasAuthorship W2963067539A5003232266 @default.
• W2963067539 hasAuthorship W2963067539A5016773523 @default.
• W2963067539 hasAuthorship W2963067539A5017341923 @default.
• W2963067539 hasAuthorship W2963067539A5020519105 @default.
• W2963067539 hasAuthorship W2963067539A5023063042 @default.
• W2963067539 hasAuthorship W2963067539A5034624734 @default.
• W2963067539 hasAuthorship W2963067539A5037330717 @default.
• W2963067539 hasAuthorship W2963067539A5039824498 @default.
• W2963067539 hasAuthorship W2963067539A5043157565 @default.
• W2963067539 hasAuthorship W2963067539A5052934298 @default.
• W2963067539 hasAuthorship W2963067539A5053353486 @default.
• W2963067539 hasAuthorship W2963067539A5057486427 @default.
• W2963067539 hasAuthorship W2963067539A5059839538 @default.
• W2963067539 hasAuthorship W2963067539A5066552050 @default.
• W2963067539 hasAuthorship W2963067539A5082287365 @default.
• W2963067539 hasAuthorship W2963067539A5083527191 @default.
• W2963067539 hasAuthorship W2963067539A5085518228 @default.
• W2963067539 hasAuthorship W2963067539A5087077844 @default.
• W2963067539 hasAuthorship W2963067539A5089354375 @default.
• W2963067539 hasAuthorship W2963067539A5091055565 @default.
• W2963067539 hasAuthorship W2963067539A5091201610 @default.
• W2963067539 hasConcept C104317684 @default.
• W2963067539 hasConcept C119054055 @default.
• W2963067539 hasConcept C120821319 @default.
• W2963067539 hasConcept C122060243 @default.
• W2963067539 hasConcept C135763542 @default.
• W2963067539 hasConcept C141231307 @default.
• W2963067539 hasConcept C153209595 @default.
• W2963067539 hasConcept C174475383 @default.
• W2963067539 hasConcept C203014093 @default.
• W2963067539 hasConcept C2780007613 @default.
• W2963067539 hasConcept C2780332060 @default.
• W2963067539 hasConcept C2780817109 @default.
• W2963067539 hasConcept C30481170 @default.
• W2963067539 hasConcept C31467283 @default.
• W2963067539 hasConcept C51679486 @default.
• W2963067539 hasConcept C53226629 @default.
• W2963067539 hasConcept C54355233 @default.
• W2963067539 hasConcept C70721500 @default.
• W2963067539 hasConcept C86803240 @default.
• W2963067539 hasConceptScore W2963067539C104317684 @default.
• W2963067539 hasConceptScore W2963067539C119054055 @default.
• W2963067539 hasConceptScore W2963067539C120821319 @default.
• W2963067539 hasConceptScore W2963067539C122060243 @default.
• W2963067539 hasConceptScore W2963067539C135763542 @default.
• W2963067539 hasConceptScore W2963067539C141231307 @default.
• W2963067539 hasConceptScore W2963067539C153209595 @default.
• W2963067539 hasConceptScore W2963067539C174475383 @default.
• W2963067539 hasConceptScore W2963067539C203014093 @default.
• W2963067539 hasConceptScore W2963067539C2780007613 @default.
• W2963067539 hasConceptScore W2963067539C2780332060 @default.
• W2963067539 hasConceptScore W2963067539C2780817109 @default.
• W2963067539 hasConceptScore W2963067539C30481170 @default.
• W2963067539 hasConceptScore W2963067539C31467283 @default.
• W2963067539 hasConceptScore W2963067539C51679486 @default.
• W2963067539 hasConceptScore W2963067539C53226629 @default.
• W2963067539 hasConceptScore W2963067539C54355233 @default.
• W2963067539 hasConceptScore W2963067539C70721500 @default.
• W2963067539 hasConceptScore W2963067539C86803240 @default.
• W2963067539 hasLocation W29630675391 @default.
• W2963067539 hasOpenAccess W2963067539 @default.
• W2963067539 hasPrimaryLocation W29630675391 @default.
• W2963067539 hasRelatedWork W2012611620 @default.
• W2963067539 hasRelatedWork W2095329844 @default.
• W2963067539 hasRelatedWork W2224180086 @default.
• W2963067539 hasRelatedWork W2311704414 @default.

• next